Collaborations

Genes-to-leads drug discovery deal signed

Published in Obesity and Diabetes Week, December 20th, 2004

Cengent Therapeutics, a structure-guided drug discovery company, announced the signing of a Genes-To-Leads drug discovery contract with Dynamis Therapeutics, Inc., a Pennsylvania based biotechnology company.

Under the agreement, Cengent will apply its proprietary platform lead identification technology, Genes To Leads, to screen for drug candidates against diabetic related kidney and heart disease, blindness and neuropathy.

The proprietary drug target of Dynamis Therapeutics, Inc., is an enzyme that causes the formation of 3-deoxyglucosone. 3-deoxyglucosone is an adversely reactive molecule that causes the formation of free radicals and AGEs,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2004-12-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry